Prevalence of liver disease in veterans with bipolar disorder or schizophrenia

Fuller, Bret E.; Rodriguez, Veronica L.; Linke, Alex; Sikirica, Mirko; Dirani, Riad; Hauser, Péter

doi:10.1016/j.genhosppsych.2011.03.006

Cited by 52 publications

(56 citation statements)

References 19 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The median prevalence estimate of hepatitis B was higher in inpatient (26.7%) than in other (18.9%) study populations. Estimates of the prevalence of hepatitis C (median: 12.3%; range: 0.7%-25.4%) in persons with SMI were extracted from 14 studies 49,61,63,70,87,95,97-104 (18 measures). In the overall US adult population, the estimated prevalence of hepatitis B is 0.3% based on clinical data (NHANES 2005-2006).…”

Section: Resultsmentioning

confidence: 99%

Review of the evidence: prevalence of medical conditions in the United States population with serious mental illness

Janssen

McGinty

Azrin

et al. 2015

General Hospital Psychiatry

132

View full text Add to dashboard Cite

Objective Persons with serious mental illness (SMI) have high rates of premature mortality from preventable medical conditions, but this group is underrepresented in epidemiologic surveys and we lack national estimates of the prevalence of conditions such as obesity and diabetes in this group. We performed a comprehensive review to synthesize estimates of the prevalence of 15 medical conditions among the population with SMI. Method We reviewed studies published in the peer-reviewed literature from January 2000-August 2012. Studies were included if they assessed prevalence in a sample of 100 or more US adults with schizophrenia or bipolar disorder. Results 57 studies were included in the review. For most medical conditions, the prevalence estimates varied considerably. For example, estimates of obesity prevalence ranged from 26% to 55%. This variation appeared to be due to differences in measurement (e.g. self-report versus clinical measures) and underlying differences in study populations. Few studies assessed prevalence in representative, community samples of persons with SMI. Conclusions In many studies, the prevalence of medical conditions among the population with SMI was higher than among the overall US population. Screening for and monitoring of these conditions should be common practice in clinical settings serving persons with SMI.

show abstract

Section: Resultsmentioning

confidence: 99%

Review of the evidence: prevalence of medical conditions in the United States population with serious mental illness

Janssen

McGinty

Azrin

et al. 2015

General Hospital Psychiatry

132

View full text Add to dashboard Cite

show abstract

“…Cross-sectionally 7.3-33.9 % are reported to suffer from any gastroenterological disorder (Beyer et al 2005 ;Thompson et al 2006 ;Oreski et al 2012 ;Fenn et al 2005 ), and the respected rate might be around 33 % for lifetime rates (Fenn et al 2005 ). Any liver disease is reported in 0.3-21 % (Kemp et al 2013 ;Perron et al 2009 ;Fenn et al 2005 ;Carney and Jones 2006 ;Fuller et al 2011 ;Laursen et al 2011 ), cirrhosis (mostly because of alcohol abuse) in 0.9-2.1 % (Perron et al 2009 ;Fuller et al 2011 ;Fenn et al 2005 ), gastritis in 0.3-15 % (Perron et al 2009 ;Fenn et al 2005 ;Kilbourne et al 2004 ) and peptic ulcer in 0.9-22 % (Goodwin et al 2009 ;Perron et al 2009 ;Subramaniam et al 2013 ;McIntyre et al 2006a ;Fenn et al 2005 ;Magalhaes et al 2012 ;Carney and Jones 2006 ;Laursen et al 2011 ). Other gastroenterological disorders are reported also like Crohn's disease (McIntyre et al 2006a ) and oesophageal varices (Fenn et al 2005 ), incontinence (Fenn et al 2005 ) and gastrointestinal fl uid and electrolyte disorders (Carney and Jones 2006 ).…”

Section: Gastroenterological Disordersmentioning

confidence: 99%

Comorbidity

Fountoulakis¹

2014

Bipolar Disorder

View full text Add to dashboard Cite

“…Among the latter, antipsychotic drugs and, especially, second generation antipsychotics (SGAs) play a pivotal role [11,12]. Particularly, clozapine and olanzapine are associated with excessive weight gain (up to 2 kg per month) [13,14], but also the metabolism of glucose and lipids is affected to a varying degree [15,16]. Non-alcoholic fatty liver disease (NAFLD), which is a commonly known complication to obesity, may also be a possible side effect of antipsychotic drug treatment, and a high prevalence of NAFLD has been observed in schizophrenia patients [16].…”

Section: Introductionmentioning

confidence: 99%

“…Particularly, clozapine and olanzapine are associated with excessive weight gain (up to 2 kg per month) [13,14], but also the metabolism of glucose and lipids is affected to a varying degree [15,16]. Non-alcoholic fatty liver disease (NAFLD), which is a commonly known complication to obesity, may also be a possible side effect of antipsychotic drug treatment, and a high prevalence of NAFLD has been observed in schizophrenia patients [16]. Thus, in the present-day clinical setting optimal antipsychotic treatment is often compromised due to antipsychotic-induced weight gain and 'dysmetabolism'.…”

Section: Introductionmentioning

confidence: 99%

Glucagon-like peptide-1 analogs against antipsychotic-induced weight gain: potential physiological benefits

Ebdrup

Knop

Ishøy

et al. 2012

BMC Med

View full text Add to dashboard Cite

BackgroundAntipsychotic-induced weight gain constitutes a major unresolved clinical problem which may ultimately be associated with reducing life expectancy by 25 years. Overweight is associated with brain deterioration, cognitive decline and poor quality of life, factors which are already compromised in normal weight patients with schizophrenia.Here we outline the current strategies against antipsychotic-induced weight gain, and we describe peripheral and cerebral effects of the gut hormone glucagon-like peptide-1 (GLP-1). Moreover, we account for similarities in brain changes between schizophrenia and overweight patients.DiscussionCurrent interventions against antipsychotic-induced weight gain do not facilitate a substantial and lasting weight loss. GLP-1 analogs used in the treatment of type 2 diabetes are associated with significant and sustained weight loss in overweight patients. Potential effects of treating schizophrenia patients with antipsychotic-induced weight gain with GLP-1 analogs are discussed.ConclusionsWe propose that adjunctive treatment with GLP-1 analogs may constitute a new avenue to treat and prevent metabolic and cerebral deficiencies in schizophrenia patients with antipsychotic-induced weight gain. Clinical research to support this idea is highly warranted.

show abstract

Prevalence of liver disease in veterans with bipolar disorder or schizophrenia

Abstract: This study in veterans shows that the presence of mental illness and its comorbidities represents a significant risk factor for the diagnosis of liver disease, including HCV and alcohol-related cirrhosis.

Cited by 52 publications

References 19 publications

Review of the evidence: prevalence of medical conditions in the United States population with serious mental illness

Review of the evidence: prevalence of medical conditions in the United States population with serious mental illness

Comorbidity

Glucagon-like peptide-1 analogs against antipsychotic-induced weight gain: potential physiological benefits

Contact Info

Product

Resources

About